drugset / Trial / NCT04727736
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen (PSA) levels.
Timeline
- Start
- 2021-05-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 259 mbq | Intravenous |
| Subject | 18F-DCFPyL | Diagnostic / imaging agent | 333 mbq | Intravenous |